Safety and efficacy of intravenous colistin in children

Kumar, Poddutoor Preetham; Giri, Swapnil Rameshwar; Shaikh, Farhan; Panigrahy, Nalinikanta; Chirla, Dinesh

doi:10.1007/s13312-015-0586-1

Cited by 12 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies revealed that the efficacy of colistin was 68%-100%, and colistin was reported to be a safe and efficient treatment of MDR A baumannii infections in children. [1][2][3][4][5] In our study we obtained sterile blood and BAL cultures during colistin treatment, supporting previous reports.…”

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecsupporting

confidence: 90%

“…2 However, studies including colistin treatment for MDR A baumannii in the pediatric population are limited. [3][4][5] In our study, our aim was to evaluate the efficacy and safety of intravenous colistin use in patients diagnosed with central line-associated bloodstream infection (CLABSI) or ventilator-associated pneumonia (VAP) caused by MDR A baumannii between January 2013 and January 2015 in the Dr. Behçet Uz Children Research And Training Hospital, İzmir, Turkey.…”

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecmentioning

confidence: 99%

“…Colistin therapy, which had decreased usage because of its nephrotoxicity and neurotoxicity in the 1980s, has become popular again. 4 Restricted studies in the pediatric age group have revealed that the incidence of colistin side effects are 0%-29%. The most common side effect is nephrotoxicity followed by neurotoxicity, which are reversible.…”

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecmentioning

confidence: 99%

See 2 more Smart Citations

Safety and efficacy of intravenous colistin use for the treatment of nosocomial multidrug-resistant Acinetobacter baumannii infections in a pediatric intensive care unit

İşgüder

Ağın

Ceylan

et al. 2016

American Journal of Infection Control

View full text Add to dashboard Cite

show abstract

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecsupporting

confidence: 90%

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecmentioning

confidence: 99%

Section: Safety and Efficacy Of Intravenous Colistin Use For The Treatment Of Nosocomial Multidrugresistant Acinetobacter Baumannii Infecmentioning

confidence: 99%

See 1 more Smart Citation

Safety and efficacy of intravenous colistin use for the treatment of nosocomial multidrug-resistant Acinetobacter baumannii infections in a pediatric intensive care unit

İşgüder

Ağın

Ceylan

et al. 2016

American Journal of Infection Control

View full text Add to dashboard Cite

show abstract

“…8,10 There are a number of studies evaluating colistin-related nephrotoxicity in the pediatric age group. 11,12 However, such studies focusing on premature children are quite few. 13 The aim of this study was to investigate the incidence of colistin-related side effects in premature neonates and to determine risk factors.…”

mentioning

confidence: 99%

Assesment of colistin related side effects in premature neonates

Aksoy¹,

Özyazıcı-Özkan²,

Tezel³

et al. 2020

Turk J Pediatr

View full text Add to dashboard Cite

Background. Colistin is an antibiotic in the polymyxin group and is especially important in the elimination of multi-drug resistant gram negative bacteria. To date, there are many studies investigating colistin related side effects, especially nephrotoxicity. However, there are few studies involving premature neonates, and this study aimed to investigate the side effects of colistin in this particular patient group. Methods. Between January 2016 and May 2019, the medical records of premature neonates treated with colistin were retrospectively reviewed. The diagnosis of acute kidney injury (AKI) was performed according to the modified neonatal KDIGO criteria. Serum electrolyte levels were recorded at the initiation of colistin treatment and 4-7 days after. Results. A total of 47 premature neonates; with a median gestational age of 27 weeks and median weight of 970 g at birth were included in the study. The median postnatal day of colistin initiation was 24 days and mean duration of colistin therapy was 15.95 ± 3.70 days. Colistin was combined with aminoglycosides in 44.6% of the patients. Acute kidney injury was documented in 17.0% of premature neonates. (n = 6 for stage 1, n = 2 for stage 2, none of the patients had stage 3). In univariate analysis, gestational age and concomitant aminoglycoside use were associated with AKI development (OR, 0.446; 95% CI 0.238-0.832; p = 0.011 and OR, 1.324; 95% CI 1.023-7.584; p = 0.024). Mean magnesium level significantly decreased after colistin treatment (1.70 ± 0.84 vs. 1.57 ± 0.29, p = 0.017) and the frequency of hypomagnesemia increased after colistin use (78.7% vs. 91.5%, p = 0.031). Frequency of elevated AST increased from 23.4% to 44.7% following colistin use (p = 0.031). Conclusions. Colistin-related side effects observed in premature neonates are not as common as in pediatric patients. Electrolyte imbalance is observed more frequently in this age group following colistin use. We suggest strict serum electrolyte level monitoring, especially magnesium, in premature neonates that are receiving colistin.

show abstract

“…Neonates 50 000 -75 000 IU/kg/day in three divided dosages 16,19 75 000 -120 000 IU/kg/day in three divided dosages have been used in this population 15 Infants and children 75 000 -150 000 IU/kg/day in three divided dosages. 16,17 Inhalation CMS < 40kg: 500 000 IU every 12 hours > 40kg: 1 000 000 IU (1MU) every 12 hours 16,20…”

Section: Dosage Based On Colistimethate Sodium (Cms)mentioning

confidence: 99%

COLISTIN: adult and paediatric guideline for South Africa, 2016

Labuschagne¹,

Schellack²,

Gous³

et al. 2016

Southern African Journal of Infectious Diseases

View full text Add to dashboard Cite

This document was created to serve as a guideline for colistin prescribing in South Africa. Antimicrobial resistance is threatening the effective prevention and treatment of a wide variety of infections, especially those that are caused by multi-drug-resistant (MDR) gram-negative bacteria. Colistin is typically used as salvage therapy, or last-line treatment, for MDR gram-negative infections. The dosing regimen should be optimised to be therapeutic and halt the emergence of resistance, whilst minimizing toxicity. This document provides evidence-based recommendations for adult and paediatric dosing, dosing in renal impairment, and the use of combination therapy to increase synergistic effects, as well as guidelines on the reconstitution and administration of colistin. This guideline is specifically aimed at healthcare workers who routinely treat patients with MDR gram-negative infections, especially in the intensive care setting.

show abstract

Safety and efficacy of intravenous colistin in children

Abstract: Colistimethate sodium is effective against carbapenem-resistant Gram-negative bacteria, and is safe in children.

Cited by 12 publications

References 13 publications

Safety and efficacy of intravenous colistin use for the treatment of nosocomial multidrug-resistant Acinetobacter baumannii infections in a pediatric intensive care unit

Safety and efficacy of intravenous colistin use for the treatment of nosocomial multidrug-resistant Acinetobacter baumannii infections in a pediatric intensive care unit

Assesment of colistin related side effects in premature neonates

COLISTIN: adult and paediatric guideline for South Africa, 2016

Contact Info

Product

Resources

About